Sandell Asset Management’s Pacira BioSciences PCRX Stock Holding History

Sandell Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25,000	Closed	-$952K	–	55
2019 Q3	$952K	Buy	+25,000	New	+$998K	0.32%	32
2019 Q2	–	Sell	-30,000	Closed	-$1.14M	–	44
2019 Q1	$1.14M	Buy	+30,000	New	+$1.17M	0.2%	36
2018 Q4	–	Sell	-50,000	Closed	-$2.46M	–	49
2018 Q3	$2.46M	Sell	50,000 -95,000	-66%	-$4.11M	0.19%	34
2018 Q2	$4.65M	Sell	145,000 -42,500	-23%	-$1.47M	0.27%	36
2018 Q1	$5.84M	Buy	+187,500	New	+$6.68M	0.65%	30

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Sandell Asset Management's PCRX Position: Q1 2020 in Review

Sandell Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 140,000 shares — an estimated $6.34M sold.

Sandell Asset Management first reported a position in PCRX in Q2 2017 and held it in 11 quarters. The position peaked at $17.2M in Q4 2017. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Sandell Asset Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
Sandell Asset Management sold 140,000 Pacira BioSciences shares in Q1 2020, an estimated $6.34M.
Sandell Asset Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 11 quarters.
Sandell Asset Management's Pacira BioSciences position peaked at $17.2M in Q4 2017.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Sandell Asset Management's 13F filing for Q1 2020, filed 15 May 2020.